The most notable development in GN has been made in MN whereby Beck et al. [61] discovered a novel antibody M-type phospholipase A (2) receptor (PLA2R) using mass spectrometry, which is now widely used in clinical practice. Here, PLA2R1 is linked to ganglioneuroma.